BMS-986189

BMS-986189 is a macrocyclic peptide that functions as a potent inhibitor of the programmed cell death ligand 1 (PD-L1), thereby blocking the interaction between PD-L1 and its receptor PD-1. This mechanism is designed to enhance immune responses against cancer cells by preventing tumor-induced immune suppression. The drug was developed primarily for oncology indications but also entered early clinical development for sepsis. It was originally developed by Bristol Myers Squibb in collaboration with PeptiDream. As of the latest updates, its development for sepsis has been discontinued after Phase 1 trials, and it remains in preclinical stages for cancer research[1][3][4][9].